This chart shows the generic pharmaceutical companies that had the most successful drug patent challenges from 2013 to 2018.
Companies that successfully challenge patents on branded drugs are granted six months of generic exclusivity.
Because first-on-market generics tend to sell at 70% or more of the price of the branded drug, the financial rewards stemming from
the market exclusivity granted for drug patent challenges can more than cover the subtantial costs of drug patent challenge and associated litigation.
The most successful patent challengers from 2013 to 2018 were
- Impax Labs Inc
- Par Pharm Inc
- Lupin Ltd
- Watson Labs Inc
- Aurobindo Pharma Ltd
- Sun Pharma Global
Copyright © DrugPatentWatch. Originally published at Most prolific drug patent challengers